PRO-KINASERESEARCH - Protein kinases - Novel Drug Targets of Post Genomic Era (FP6-LIFESCIHEALTH) (2004-03-01 - 2009-02-28) (»add to infobox)

Raimo TUOMINEN, Kurt HOSTETTMANN, Philip COHEN, János SZÖLLÕSI, Thierry LANGER, Leonardo SCAPOZZA, Louise JOHNSON, Peter GOEKJIAN, Lorenzo A. PINNA, Peter Joseph Jacques PARKER, Charles JAFFE, Yehezkel BEN-ARI, Angelika VOLLMAR, Stein Ove DOSKELAND, Janet LORD, Carlo GAMBACORTI-PASSERINI, Michael KUBBUTAT, Paul PECHAN, Serge TIMSIT, Thierry LANGER, Peter VAN DIJKEN, Conrad KUNICK, Johann HOFMANN

HELSINGIN YLIOPISTO (FI181 - Uusimaa) (Finland), UNIVERSITE DE LAUSANNE (CH022 - Freiburg) (Switzerland), UNIVERSITY OF DUNDEE (UKM21 - Angus and Dundee City) (Great Britain), DEBRECENI EGYETEM (HU321 - Hajdu-Bihar) (Hungary), UNIVERSITAET INNSBRUCK (AT332 - Innsbruck) (Austria), EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH (CH04 - Zürich) (Switzerland), THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (UKJ14 - Oxfordshire) (Great Britain), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR716 - Rhône) (France), FONDAZIONE PER LA RICERCA BIOMEDICA AVANZATA (ITD36 - Padova) (Italy), CANCER RESEARCH UK (UKI11 - Inner London - West) (Great Britain), THE HEBREW UNIVERSITY OF JERUSALEM (ME04 - Israel) (Israel), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR101 - Paris) (France), LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE212 - München, Kreisfreie Stadt) (Germany), UNIVERSITETET I BERGEN (NO051 - Hordaland) (Norway), THE UNIVERSITY OF BIRMINGHAM (UKG31 - Birmingham) (Great Britain), ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI (ITC45 - Milano) (Italy), KTB TUMORFORSCHUNGSGESELLSCHAFT (DE131 - Freiburg im Breisgau, Stadtkreis) (Germany), C3 BIO GMBH (DE21H - München, Landkreis) (Germany), NEUROKIN SARL (FR824 - Bouches-du-Rhône) (France), INTELIGAND SOFTWARE-ENTWICKLUNGS-UND CONSULTING GMBH (AT127 - Wiener Umland/Südteil) (Austria), PEPSCAN SYSTEMS BV (NL230 - Flevoland) (Netherlands), TECHNISCHE UNIVERSITAET CAROLO-WILHELMINA ZU BRAUNSCHWEIG (DE911 - Braunschweig, Kreisfreie Stadt) (Germany), MEDIZINISCHE UNIVERSITAET INNSBRUCK (AT332 - Innsbruck) (Austria)

Nearly all aspects of cell life (and death) are controlled by protein phosphorylation catalysed by protein kinases (PKs). PKs belong to the largest single family of enzymes, numbering over 500 and accouting for almost 2% of the proteins encoded by the human genome. Recent success in drug discovery (e.g. Imatinib, GlivecR) demonstrate that PKs are excellent drug targets. The Pro-KinaseResearch consortium will combine European expertise on basic research on PKs and that on rational drug discovery, in order to develop new drug candidates and treatment strategies for major diseases like cancer, autoimmune disorders, vascular diseases and degenerative brain diseases. Thus, the aim of this IP is to study PKs as drug targets for more effective and better tolerated drug therapies meeting the needs of ageing population. The joint effort will focus on the biochemical properties and structure function relationships of a wide variety of PKs having the potential as pharmacological targets. We will evaluate the regulatory domains, catalytic domains and also anchoring proteins of various PKs, as drug targets. natural compounds from European biosphere, e.g. Cyanobacteria, and compounds from combinatorial chemistry, chemical libraries, affecting activity of PKs will be analysed to gain knowledge of their structure/activity relationship. These compounds will be used as model drugs or templates for a rational drug design where new compounds will be modelled and synthesised. This consortium has a broad range of bio-activity assays to study the efficacy and toxicity of the new compounds. The consortium includes academic groups with unique expertise in biochemistry, structural crystallography, synthetic organic chemistry, lead structure optimisation and other fields of rational drug discovery ; clinically oriented groups with proven experience in animal models and phase I-II clinical studies under GCP quidelines ; and SME partners to assure a quick transfer of knowledge.

PERSONS (23/23)

RELATED NAVIGATION AREA(S) (2/2)